Soonchunhyang Med Sci.
2018 Jun;24(1):81-84. 10.0000/sms.2018.24.1.81.
Tamoxifen-Induced Non-alcoholic Steatohepatitis Cirrhosis
- Affiliations
-
- 1Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea. cocorico99@gmail.com
- 2Department of Pathology, Ajou University School of Medicine, Suwon, Korea.
- KMID: 2437772
- DOI: http://doi.org/10.0000/sms.2018.24.1.81
Abstract
- Non-alcoholic fatty liver disease has been observed in over 30% of patients who have received tamoxifen therapy. However, tamoxifen-induced non-alcoholic steatohepatitis (NASH) cirrhosis has never been reported in Korea. A 41-year-old woman was diagnosed with invasive ductal carcinoma in the left breast. She had well-controlled type 2 diabetes mellitus, hypertension, and chronic hepatitis B. Ultrasonography showed mild fatty liver. Chronic hepatitis B had been treated with clevudine one month before the diagnosis of breast cancer. The patient was diagnosed with NASH cirrhosis 39 months after tamoxifen treatment. Careful observation for the development of NASH cirrhosis is warranted during tamoxifen therapy.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Hepatocellular Carcinoma Arising from Non-Cirrhotic Non-Alcoholic Steatohepatitis
- Pathogenesis of Nonalcoholic Steatohepatitis: Role of Lipid Peroxidation, Mitochondrial Dysfunction and Cytokines
- The Cause and Complication of Liver Cirrhosis during the Reccent 5 Years
- Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome
- Comparison of bacterial infection rate between patients with alcoholic liver cirrhosis and viral liver cirrhosis
